New Delhi: Recently approved COVID antiviral drug Molnupiravir has been launched in India at Rs 1,399 for a five-day course for mild to moderate infection.
The said vaccine got its approval from an expert panel of the Central Drugs Standard Control Organisation (CDSCO) for use in an emergency situation.
Apart from Molnupiravir, the CDSCO has also granted the emergency use of COVOVAX produced by the Serum Institute of India.
Molnupiravir is an antiviral medication that inhibits the replication of certain RNA viruses. The drug is used to treat those who are infected by SARS-CoV-2.
The recommended dose of this drug is 800mg twice a day for five days.
Reportedly, over a dozen pharma companies including Torrent, Cipla, Sun Pharma, Dr Reddy`s, Natco, Mylan, and Hetero are in the process to manufacture the oral pill.
Molnupiravir is developed by the MSD and Ridgeback Biotherapeutics and it is the first oral anti-Covid pill approved by UK`s drug regulator.
Notably, the US Food and Drug Administration (USFDA) has also cleared Molnupiravir for the treatment of mild-to-moderate COVID-19 in adults, and for those who are at a high risk to severe disease.
Also watch: